One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry study

One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry study

Abstract Background Randomized clinical trials have demonstrated efficacy and safety of erenumab. The aim of this study is to evaluate the effectiveness and safety of erenumab in a real-world setting in French patients with migraine associated with extreme unmet needs. Methods This is a one year-pro...

Full description

Bibliographic Details
Main Authors:	M. Lanteri-Minet, R. Fabre, C. Martin, K. Pradat, A. Alchaar, E. Bozzolo, M. L. Duchene, E. K. Van Obberghen, A. Donnet, D. Fontaine
Format:	Article
Language:	English
Published:	BMC 2023-11-01
Series:	The Journal of Headache and Pain
Subjects:	High frequency episodic migraine Chronic migraine Medication overuse Erenumab CGRP Monoclonal antibodies
Online Access:	https://doi.org/10.1186/s10194-023-01680-4

Similar Items

A prospective real-world analysis of erenumab in refractory chronic migraine
by: Giorgio Lambru, et al.
Published: (2020-06-01)

Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials
by: Stewart J Tepper, et al.
Published: (2021-07-01)

Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis
by: Anna P. Andreou, et al.
Published: (2022-11-01)

Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months
by: Edoardo Caronna, et al.
Published: (2021-10-01)

Raynaud's phenomenon secondary to erenumab in a patient with chronic migraine
by: Agaath Hedina Manickam, et al.
Published: (2021-08-01)

Erenumab efficacy predictors for chronic migraine
by: Nina V. Vashchenko
Published: (2022-02-01)

A proof-of-concept study on CGRP plasma levels of migraineurs during a 6-month treatment with ERENUMAB
by: Giuseppe Tringali, et al.
Published: (2020-10-01)

Assessment and characteristics of Erenumab therapy on migraine management
by: Haitham Saeed, et al.
Published: (2022-08-01)

Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation
by: Michael Lowe, et al.
Published: (2022-07-01)

Efficacy and safety of erenumab in women with a history of menstrual migraine
by: Jelena M. Pavlovic, et al.
Published: (2020-08-01)

Real-Life Analysis with Erenumab: First Target Therapy in the Episodic and Chronic Migraine’s Prophylaxis
by: Zaira Maraia, et al.
Published: (2021-09-01)

Erenumab Impact on Sleep Assessed With Questionnaires and Home-Polysomnography in Patients With Migraine: The ERESON Study
by: Gaia Pellitteri, et al.
Published: (2022-05-01)

Efficacy of Erenumab for Migraine Prevention in Japanese Patients with Episodic and Chronic Migraine: Results of a Post-Hoc Pooled Analysis
by: Shigekazu Kitamura, et al.
Published: (2023-09-01)

Early onset of efficacy with erenumab in patients with episodic and chronic migraine
by: Todd Schwedt, et al.
Published: (2018-10-01)

A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine
by: Saval Khanal, et al.
Published: (2022-09-01)

Erenumab in Mechanism-based Migraine Treatment
by: Aynur Özge, et al.
Published: (2021-09-01)

Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis
by: Patricia Pozo-Rosich, et al.
Published: (2024-03-01)

Cerebral Blood Flow and Other Predictors of Responsiveness to Erenumab and Fremanezumab in Migraine—A Real-Life Study
by: Magdalena Nowaczewska, et al.
Published: (2022-05-01)

Serum CGRP in migraine patients using erenumab as preventive treatment
by: Simone de Vries Lentsch, et al.
Published: (2022-09-01)

Erenumab and Possible CGRP Effect on Chronotype in Chronic Migraine: A Real-Life Study of 12 Months Treatment
by: Laura Pilati, et al.
Published: (2023-05-01)

Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience
by: Antonio Russo, et al.
Published: (2020-06-01)

MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention
by: Robert Belvís, et al.
Published: (2021-07-01)

Erenumab for Migraine Prevention in a 1-Year Compassionate Use Program: Efficacy, Tolerability, and Differences Between Clinical Phenotypes
by: Jean Schoenen, et al.
Published: (2021-12-01)

CGRP-targeted medication in chronic migraine - systematic review
by: Renato Oliveira, et al.
Published: (2024-04-01)

Six-month therapy of CGRP monoclonal antibodies in real-world clinical practice: an interim analysis of efficacy and safety data
by: N. V. Vashchenko, et al.
Published: (2022-01-01)

The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal
by: Raffaele Ornello, et al.
Published: (2019-10-01)

Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor
by: Hans-Christoph Diener, et al.
Published: (2020-04-01)

Migraine Treatment Using Erenumab: Can Lead to a Cognitive and Psychological Qualitative Improvement?
by: Michele Torrisi, et al.
Published: (2023-05-01)

Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment – real world outcomes
by: J. Talbot, et al.
Published: (2021-01-01)

Long-Term Treatment with the Calcitonin Gene-Related Peptide Receptor Antagonist Erenumab in CADASIL: Two Case Reports
by: Maria Albanese, et al.
Published: (2024-03-01)

Changes in Cerebral Blood Flow after Erenumab Treatment in Good and Non-Responders—A Pilot Study of Migraine Patients
by: Magdalena Nowaczewska, et al.
Published: (2021-06-01)

Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study
by: Hannah Schenk, et al.
Published: (2022-05-01)

Real-world effectiveness of erenumab in Japanese patients with migraine
by: Keisuke Suzuki, et al.
Published: (2024-02-01)

Monoclonal antibodies for chronic migraine and medication overuse headache: A real-world study
by: Abouch V. Krymchantowski, et al.
Published: (2023-03-01)

Erenumab in highly therapy-refractory migraine patients: First German real-world evidence
by: Armin Scheffler, et al.
Published: (2020-07-01)

CGRP Inhibitors and Oxidative Stress Biomarkers in Resistant Migraine: A Real-Life Study with Erenumab, Fremanezumab, and Galcanezumab
by: Ciro De Luca, et al.
Published: (2021-10-01)

Initial experience with novel CGRP-receptor inhibitor therapy in Migraine in the United Arab Emirates: a retrospective observational study
by: Bui Bao Khanh Dinh, et al.
Published: (2021-12-01)

Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination
by: Bianca Raffaelli, et al.
Published: (2019-06-01)

Predictors of response to erenumab after 12 months of treatment
by: Carlo Baraldi, et al.
Published: (2021-08-01)

Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial
by: Roberto De Icco, et al.
Published: (2022-09-01)